Cases 21 - 30 of 141
In re: Entresto (Sacubitril/Valsartan) Patent Litigation
as 1:2020md02930
Counter Claimant:
Biocon Pharma Limited, Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd. and others
Not Classified By Court:
Hetero USA Inc.,, Torrent Pharma Inc., Zydus Pharmaceuticals (USA) Inc. and others
In Re:
Entresto (Sacubitril/Valsartan) Patent Litigation
Counter Defendant:
Novartis Pharmaceuticals Corporation
Defendant:
Noratech Labs, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Takeda Pharmaceuticals U.S.A., Inc. v. Mylan Pharmaceuticals Inc.
as 1:2019cv02216
Defendant:
Mylan Pharmaceuticals Inc.
Plaintiff:
Takeda Pharmaceuticals U.S.A., Inc.
3Rd Party Defendant:
Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc.
Intervenor:
Par Pharmaceutical Inc.
Cause Of Action: 35 U.S.C. § 271
Novartis Pharmaceuticals Corporation v. Dr. Reddys Laboratories, Inc. et al
as 1:2019cv02053
Defendant:
MSN Laboratories Private Limited, Dr. Reddys Laboratories, Inc., Hetero USA Inc. and others
Plaintiff:
Novartis Pharmaceuticals Corporation
Cause Of Action: 35 U.S.C. § 271
Pfizer Inc. et al v. Mylan Pharmaceuticals Inc.
as 1:2019cv01863
Plaintiff:
Warner-Lambert Company LLC, PF Prism C.V., Pfizer Manufacturing Holdings LLC and others
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271
In re: Palbociclib Patent Litigation
as 1:2019md02912
Not Classified By Court:
Aizant Drug Research Solutions Pvt. Ltd., Hetero USA Inc., Teva Pharmaceuticals USA, Inc. and others
In Re:
In re: Palbociclib Patent Litigation
Cause Of Action: 35 U.S.C. § 271
Janssen Pharmaceuticals, Inc. et al v. Mylan Laboratories Limited et al
as 1:2019cv01488
Plaintiff:
Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.
Defendant:
Mylan Pharmaceuticals Inc., Mylan Laboratories Limited and Mylan Institutional LLC
Cause Of Action: 35 U.S.C. § 271
Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc. et al
as 1:2019cv01489
Defendant:
Mylan Pharmaceuticals Inc.
Plaintiff:
Merck Sharp & Dohme Corp.
Cause Of Action: 35 U.S.C. § 271
In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
as 1:2019md02902
Counter Defendant:
Merck Sharp & Dohme Corp.
Not Classified By Court:
Teva Pharmaceuticals USA, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and others
Counter Claimant:
Macleods Pharmaceuticals Limited
In Re:
In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
Defendant:
Accord Healthcare, Inc., Teva Pharmaceutical Industries Ltd., Inventia Healthcare Ltd. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Keryx Biopharmaceuticals, Inc et al v. Mylan Pharmaceuticals Inc.
as 1:2019cv01445
Plaintiff:
Panion & BF Biotech, Inc., Keryx Biopharmaceuticals, Inc. and Chen Hsing Hsu
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271
In re: Auryxia (Ferric Citrate) Patent Litigation
as 1:2019md02896
Not Classified By Court:
Chemo Research S.L., Insud Pharma S.L., Teva Pharmaceuticals USA, Inc. and others
Counter Defendant:
Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc. and Chen Hsing Hsu
Counter Claimant:
Lupin Atlantis Holdings SA and Lupin Ltd.
In Re:
In re: Auryxia (Ferric Citrate) Patent Litigation
Cause Of Action: 35 U.S.C. § 271
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
